Abbott Labs (ABT) Stock Forecast & Price Target

Abbott Laboratories is viewed constructively because its near-term guidance reset appears driven by temporary commercialization and market-access issues in electrophysiology and diabetes, rather than a deterioration in its long-term innovation engine. The company’s diversified base is still performing well, with Nutrition at about $2.3 billion in 3Q26 revenue and 4.9% comparable growth, Diagnostics at about $1.6 billion and 8% growth, and strong momentum in Rhythm Management and Core Lab. With catalysts such as Volt, Libre Duo in December, a January 2027 formulary win, and the planned nutrition separation expected to lift margins and sharpen growth, the stock’s valuation near ten-year lows around 17x 2027 EPS looks overly compressed.

Abbott Laboratories is facing a negative fundamental setup because the business is exposed to multiple simultaneous headwinds in its “Big Three” and “Fab Five” categories, with added pressure from competition in MitraClip, Libre, and Amulet, plus weaker-than-expected Covid-19 testing demand. The outlook is further clouded by macro and operational risks such as inflation, FX, supply chain disruptions, geopolitical risk, and possible economic recession, all of which could offset elective procedure recovery and R&D investment returns. Even with 2026 revised revenue of $49.994B and adj. EPS of $5.52, the need to lower 2027 and 2028 estimates and assume about a 1-point FX headwind signals slower momentum and limited upside.